



US010472379B2

(12) **United States Patent**
Garnett

(10) **Patent No.:** **US 10,472,379 B2**

(45) **Date of Patent:** **Nov. 12, 2019**

(54) **RUTHENIUM-SPHINGOMYELIN COMPLEXES AND METHODS FOR THEIR USE IN THE TREATMENT OF TUMORS**

(58) **Field of Classification Search**
None
See application file for complete search history.

(71) Applicant: **Garnett McKean Lab, Inc.**, Bohemia, NY (US)

(56) **References Cited**

(72) Inventor: **Merrill Garnett**, East Islip, NY (US)

U.S. PATENT DOCUMENTS

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

5,686,113 A * 11/1997 Speaker A61K 9/1652
424/490
2006/0128912 A1 6/2006 Piers et al.
2013/0116458 A1 5/2013 Couturier et al.
2014/0199407 A1* 7/2014 Garnett C07F 15/0066
424/502

(21) Appl. No.: **15/589,828**

OTHER PUBLICATIONS

(22) Filed: **May 8, 2017**

“The structure of a typical antibody molecule” from Immunobiology: The Immune System in Health and Disease. 5th edition., Janeway CA Jr, Travers P, Walport M, et al. New York: Garland Science; 2001. (Year: 2001).*

(65) **Prior Publication Data**

US 2018/0051045 A1 Feb. 22, 2018

(Continued)

Related U.S. Application Data

(60) Provisional application No. 62/339,699, filed on May 20, 2016.

Primary Examiner — Nissa M Westerberg
(74) *Attorney, Agent, or Firm* — McCarter & English, LLP; Beverly W. Lubit

(51) **Int. Cl.**
C07F 15/00 (2006.01)
A61K 33/24 (2019.01)
C07K 14/47 (2006.01)
A61K 47/54 (2017.01)
A61K 47/68 (2017.01)
C07K 5/062 (2006.01)

(57) **ABSTRACT**
The described invention provides a compound comprising an organometallic complex comprising a core of ruthenium and sphingomyelin, with the option of added zinc, that, in a therapeutic amount, through further connections with contributing organic ligands, are effective as chemotherapeutic agents that have an anti-tumor or anti-cancer effect on a tumor comprising tumor cells including a cytotoxic effect on of the tumor cells, inhibition of the growth of the tumor comprising the tumor cells, inhibition of migration of the tumor cells, or any combination of these effects.

(52) **U.S. Cl.**
CPC **C07F 15/0046** (2013.01); **A61K 33/24** (2013.01); **A61K 47/547** (2017.08); **A61K 47/548** (2017.08); **A61K 47/6803** (2017.08); **C07K 5/0606** (2013.01); **C07K 14/4717** (2013.01)

40 Claims, 20 Drawing Sheets

